Gilpin Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Gilpin Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.64K	Hold	302	–	–	﹤0.01%	489
2026 Q2	$5.11K	Hold	302	–	–	﹤0.01%	368
2026 Q1	$3.87K	Hold	302	–	–	﹤0.01%	376
2025 Q4	$2.71K	Buy	+302	New	+$4.16K	﹤0.01%	375

Other funds holding NTLA

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Gilpin Wealth Management's NTLA Position: Q3 2026 in Review

Gilpin Wealth Management held its Intellia Therapeutics (NTLA) position steady in Q3 2026 at 302 shares worth $3.64K. The position accounts for ﹤0.01% of the portfolio, ranked #489.

Gilpin Wealth Management first reported a position in NTLA in Q4 2025 and has held it in 4 quarters since. The position peaked at $5.11K in Q2 2026. 6 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

Gilpin Wealth Management held 302 shares of Intellia Therapeutics worth $3.64K as of Q3 2026.
Gilpin Wealth Management left its Intellia Therapeutics share count unchanged in Q3 2026.
Intellia Therapeutics made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #489 holding.
Gilpin Wealth Management first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 4 quarters since.
Gilpin Wealth Management's Intellia Therapeutics position peaked at $5.11K in Q2 2026.
6 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.